SloveniaSlovenia

Barr to purchase Pliva for $2.2 billion, beating rival Actavis

21.07.2006

Zagreb – In the bidding race between the Icelandic Actavis Group and US Barr Pharmaceuticals Inc. for the takeover of the Croatian biogenerics producer Pliva d.d., the company ultimately opted for Barr’s offer. Both companies’ offers have been carefully reviewed by Pliva’s Supervisory and Management Boards, who have been advised by Deutsche Bank.
Under the terms of Barr’s proposal, Pliva’s shareholders will receive HRK705 (Euro99) in cash for each Pliva share held. Shareholders will additionally be entitled to a dividend of HRK12 (Euro1.70) per share, which values the whole deal at some $2.2 billion (Euro1.7 billion). The proposal is conditional upon antitrust approvals in Germany and the US. Barr’s offer price represents a 81-percent premium to Pliva’s average share price of HRK389 (Euro54.50) per ordinary share for the twelve months to 16 March 2006, the day before Pliva received the initial indicative non-binding proposal from Actavis of HRK 630 (Euro88) per Pliva share.
The combination of Pliva and Barr will expand geographic coverage and create a global pharmaceutical giant with annual revenues of about $2.5bn (Euro2bn).
The enlarged company will have a fully integrated generics platform with manu-facturing, development and marketing expertise, with a low-cost manufacturing base situated in eastern Europe and an extensive European and North American distribution and sales network.

SloveniaSlovenia

12.08.2005

Zagreb - Croatia's Government passed a new law on genetically modified organisms (GMO), which replaces the “biotechnology-regulating provisions” of the Law on the Protection of Nature that up to now regulated the importation,...

SloveniaSlovenia

10.07.2005

Ljubljana - Slovenian pharma company Pharmaswiss and Swiss pharma group Helsinn Healthcare SA have signed a licensing agreement granting Pharma-swiss the exclusive license and distribution rights for ALOXI®, a strong and...

SloveniaSlovenia

10.07.2005

Brac - The “Fall 2005 Course on Bioprocess Engineering”, organized by the EFB's Working Group on Bioreactor Performance in collaboration with the European Section on Biochemical Engineering Science, will be held from September...

SloveniaSlovenia

05.02.2005

Zagreb - The 4th International Conference on “Biotechnology and Immunomodulatory Drugs” will open its gates from February 20-23, 2005, in Zagreb, Croatia. Organized amongst others by the Croatian Society of Biotechnology and...

SloveniaSlovenia

09.10.2004

Ljubljana - Slovenia's supreme court has rejected an appeal by US-drug group Merck & Co. Inc. in August, ending a 10-year patent dispute with local drug maker Krka d.d. over one of its best-selling drug. The court rejected a...

SloveniaSlovenia

06.08.2004

Opatija - Nutrition-related biotechnology has been subject to many controverse public debates lately. The organizers of the “2nd Central European Meeting - 5th Croatian Congress of Food Technologists, Biotechnologists und...

SloveniaSlovenia

09.04.2004

Ljubljana - BIA Separations, specialized in the short monolithic column technology, will hold the “First Summer School on Monoliths for Biochro-matography, Bioconversion, and So-lid Phase Synthesis” in Potoroz, Slo-venia, from...

SloveniaSlovenia

05.03.2004

Menges - Lek Pharmaceuticals inaugurated a new manufacturing plant (PORT1) for the production of biopharmaceuticals - such as human proteins for therapeutic applications - near the Slovenian capital Lubljana in Menges in early...

SloveniaSlovenia

05.02.2004

Ljubljana - Slovenian pharmaceutical company Lek d.d. successfully defended in late December its patent EP 1 095 037, which covers Lek's synthesis of Ome-prazole before the Board of Appeal of the European Patent Office....

SloveniaSlovenia

23.11.2003

Ljubljana - Scientists at the Department of Biochemistry and Molecular Biology, Jozef Stefan Institute, Ljubljana, have identified an intracellular membrane receptor for a snake venom secretory phospholipase A (sPLA). The...

Displaying results 11 to 20 out of 22

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-slovenia/browse/1/article/barr-to-purchase-pliva-for-22-billion-beating-rival-actavis.html

Image Gallery

Stock list

All quotes

TOP

  • MORPHOSYS (D)62.00 EUR11.8%
  • BIOINVENT INTERNATIONAL AB (S)2.96 SEK10.9%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%

FLOP

  • CYTOS (CH)0.17 CHF-26.1%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)9.94 USD-9.7%

TOP

  • CO.DON (D)3.30 EUR88.6%
  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.92 EUR50.8%

FLOP

  • CYTOS (CH)0.17 CHF-94.1%
  • BIONOR PHARMA (N)2.11 NOK-49.0%
  • GW PHARMACEUTICALS (UK)219.25 GBP-39.6%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6143.9%
  • IXICO (UK)71.50 GBP807.4%
  • PLETHORA (UK)10.62 GBP585.2%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.7%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 16.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper